Quetiapine

  • 1 lab in 1 country
  • Funder: Novo Nordisk Fonden
  • Humans1
  • In silico1

Associations

1

Major adverse cardiovascular events

downin humans1

1 study
  1. Quetiapine lowers the risk of major adverse cardiovascular events in humans (IRR 0.68, 95% CI 0.58 to 0.80).

    “quetiapine (0.68, 95% CI 0.58 to 0.80)”

    Humanscompared with risperidone, first 30 days of treatment30 days

    Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons

    Journal of the American Heart Association1 Sep 2015

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 02 in 12 months